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Retroviruses differ in their preferences for sites for viral DNA integration in the chromosomes of infected cells. Human
immunodeficiency virus (HIV) integrates preferentially within active transcription units, whereas murine leukemia virus
(MLV) integrates preferentially near transcription start sites and CpG islands. We investigated the viral determinants of
integration-site selection using HIV chimeras with MLV genes substituted for their HIV counterparts. We found that
transferring the MLV integrase (IN) coding region into HIV (to make HIVmIN) caused the hybrid to integrate with a
specificity close to that of MLV. Addition of MLV gag (to make HIVmGagmIN) further increased the similarity of target-
site selection to that of MLV. A chimeric virus with MLV Gag only (HIVmGag) displayed targeting preferences different
from that of both HIV and MLV, further implicating Gag proteins in targeting as well as IN. We also report a genome-
wide analysis indicating that MLV, but not HIV, favors integration near DNase I–hypersensitive sites (i.e., +/– 1 kb), and
that HIVmIN and HIVmGagmIN also favored integration near these features. These findings reveal that IN is the
principal viral determinant of integration specificity; they also reveal a new role for Gag-derived proteins, and
strengthen models for integration targeting based on tethering of viral IN proteins to host proteins.
Citation: Lewinski MK, Yamashita M, Emerman M, Ciuffi A, Marshall H, et al. (2006) Retroviral DNA integration: Viral and cellular determinants of target-site selection. PLoS
Pathog 2(6): e60. DOI: 10.1371/journal.ppat.0020060
Introduction
The selection of target sites for integration of retroviral
DNA is central to the biology of retroviruses and the
application of retroviral vectors to gene therapy. The recent
setbacks in human gene-therapy trials, in which a therapeutic
retroviral vector integrated near the LMO-2 proto-oncogene
and caused leukemia-like illness in three patients [1–3], have
focused particular attention on the mechanisms responsible
for integration targeting. Here we map the retroviral
determinants of integration-target site–selection and inves-
tigate candidate mechanisms.
The basic DNA cleavage and joining reactions mediating
retroviral integration are common among retroviruses
(summarized in Figure 1A), but integration in vivo shows
pronounced favored and disfavored chromosomal regions
that differ among retroviruses. Retroviral integration-site
selection is not strongly sequence-speciﬁc with respect to the
target DNA at the point of joining, though a weakly conserved
palindromic sequence can be detected when many integra-
tion-target sites are aligned [4–7]. Early studies of murine
leukemia virus (MLV) integration targeting led to the
suggestion that integration may be favored in open chroma-
tin [8], since a positive correlation was detected between
integration frequency and DNase I–hypersensitive sites [9,10].
More recently, the completion of the draft human genome
sequence has allowed systematic studies of integration
targeting by high-throughput sequencing of integration
acceptor sites [11–14]. Human immunodeﬁciency virus
(HIV) integration sites are found predominantly in active
transcription units [11,13]. A cellular protein, lens epithe-
lium–derived growth factor (LEDGF/p75), binds HIV IN [15–
18] and is partially responsible for favored integration in
genes [19]. For MLV, in contrast, roughly 25% of integration
events are near transcription start sites and associated CpG
islands, while integration within transcription units is only
slightly favored [14]. Avian sarcoma-leukosis virus (ASLV)
shows the most random pattern of integration-site selec-
tion—ASLV favors transcription units only weakly and does
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retroviruses studied in detail, three different patterns of
favored integration sites were found.
Here we investigate the requirements for integration
targeting using chimeric viruses in which gene segments of
MLV were substituted for the corresponding segments of the
HIV genome (Figure 1B). The chimeras contained MLV gag
gene segments substituted for HIV gag (HIVmGag) [20], MLV
IN substituted for HIV IN (HIVmIN) [21], or both MLV gag
and MLV IN substituted for their HIV counterparts (HIVm-
GagmIN) [21].
Previous characterization has shown that these viruses
differ in their ability to infect interphase cells, and that this
property maps to the gag gene polyprotein precursor [20,21].
MLV integrates only after mitosis, while HIV can integrate at
any time during the cell cycle. The chimeric viruses HIVmGag
and HIVmGagmIN show the same requirement for cell
division as does MLV [20,21], while HIVmIN, like HIV, can
infect non-dividing cells [21] (summarized in Figure 1B). Thus
MLV Gag imposes the requirement for cell division on HIV.
Consequently, tests of integration-target site–selection by
these chimeras provide an opportunity to probe the inﬂuence
of cell-cycle progression on integration-target site–selection.
Integration-site selection by the chimeric and control
viruses was assayed by cloning and sequencing 2,440 junctions
between human and proviral DNA generated by infection of
human cells. We found that HIVmIN and HIVmGagmIN
favored integration near transcription start sites and CpG
islands, paralleling the preferences of MLV and implicating
IN as the main speciﬁcity determinant. The resemblance was
closest between MLV and HIVmGagmIN, implicating Gag as a
cofactor for targeting as well as IN. HIVmGag exhibited a
phenotype that did not resemble either parent—it did not
favor transcription starts and CpG islands like MLV, and it
did not favor integration in transcription units or gene-rich
regions as strongly as did HIV, further implicating Gag as well
as IN. In addition, we used new genome-wide data on
preferential DNase I cleavage sites [22] to analyze the
relationship with favored integration sites, and found that
MLV favored integration within 1 kb of DNase I cleavage
sites, as did the HIVmIN and HIVmGagmIN chimeras.
However, HIV, ASLV, and L1 retrotransposons did not favor
these sites, indicating that possible open chromatin marked
by DNase I cleavage sites was not globally favorable for
integration of new DNA sequences. This result is more
consistent with models based on speciﬁc interactions between
MLV IN and cellular proteins bound near DNase I cleavage
sites. These data elucidate the viral determinants of integra-
tion targeting, disclose a role for Gag in integration, and
indicate that models for targeting based solely on open
chromatin or cell-cycle effects are unlikely to be correct.
Results
Cloning and Analysis of Integration Sites
The chimeric viruses used in this study were deleted for the
env gene and complemented with the vesicular stomatitis virus
G protein (VSV-G) to boost titer and restrict infection to a
single round. These chimeras were less infectious than the
wild-type virus [20,21], so the puromycin resistance gene was
cloned in place of nef, allowing infected cells to be selected
with puromycin to enrich for provirus-containing cells. Vpr
was also deleted because of its cellular toxicity [23]. In order to
control for possible biases in integration-site recovery due to
puromycin selection, control infections were carried out with
an HIV derivative transducing the puromycin resistance gene
(termed ‘‘HIVPuro’’) and an MLV vector (LPCX) also trans-
ducing the puromycin resistance gene (termed ‘‘MLVPuro’’).
Attempts to make reciprocal constructs (HIV gene segments
into an MLV background) did not yield infectious viruses
(unpublished data). HeLa cells were chosen as infection target
cells because they are highly susceptible to infection and
Figure 1. Retroviral DNA Integration and the Chimeric Viruses Used in This Study
(A) The DNA breaking and joining reactions mediating integration. Gray ovals represent integrase monomers, thick red lines represent viral DNA, black
lines represent target DNA, and dots represent 59 ends. (1) Linear blunt-ended viral cDNA is bound by integrase as part of the preintegration complex.
(2) Integrase removes two nucleotides from the 39 ends of the viral DNA, exposing recessed 39 hydroxyl groups. (3) IN joins the recessed 39 ends of viral
DNA to the target DNA. (4) Unpairing of the target DNA between the joined ends of the viral DNA yields gaps in the target DNA. (5) DNA repair enzymes
fill in the gaps. (6) The provirus is flanked by repeated segments of the target DNA.
(B) Chimeric HIV derivatives containing segments of MLV. At the top is the HIV parent virus, with vpr and env inactivated and the puromycin resistance
gene in place of nef. Following that are the chimeras, with substitutions of MLV gag gene segments (MA-, p12-, and CA-encoding regions) for HIV MA
and CA, or substitution of MLV IN for HIV IN, or both [20,21]. The MLV genome (indicated by an asterisk) is shown for comparison. The MLV used in this
study (MLVPuro) was an MLV-based vector (LPCX) encoding the puromycin resistance gene with Gag, Pol, and Env provided in trans. Although we refer
to ‘‘Gag’’ in the text, we note that Gag is in fact a polyprotein which is cleaved into individual functional proteins by the action of the viral protease.
(C) Target-sequence duplication lengths made by HIV, MLV, and the chimeric viruses.
(D) Primary sequences at the site of integration for HIV, MLV, the chimeric viruses, and a previously published MLV dataset (MLV-Burgess). On the x-axis
are the top strand positions surrounding the point of integration, which is represented by the blue arrow and line (between positions  1 and 0). For
each dataset, the proportion of each base at a given location was divided by the proportion of that base in the matched random control set, such that a
base with a y value .1 is present at an increased frequency, while a base with a y value ,1 is present at a decreased frequency compared to random
sites. A dashed red box surrounds the target sequence that is duplicated upon integration.
DOI: 10.1371/journal.ppat.0020060.g001
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Synopsis
A required step in the replication cycle of retroviruses is the
integration of a DNA copy of the viral genome into a host cell
chromosome. Recent studies have shown that human immunode-
ficiency virus (HIV) and murine leukemia virus (MLV) favor
integration near different chromosomal features. HIV preferentially
targets active genes, while MLV prefers integration near start sites of
gene transcription. The authors investigated integration-target site–
selection by HIV derivatives substituted with segments of MLV to
determine which viral proteins are responsible for integration-
targeting preferences. They found that the viral integrase protein is
the dominant determinant of integration-site selection, probably
through its tethering to cellular proteins bound near preferred
genomic regions. In addition, components of the viral structural
polyprotein, Gag, appear to be involved in targeting. These findings
provide a functional map of the viral proteins involved in directing
integration-site selection.PLoS Pathogens | www.plospathogens.org June 2006 | Volume 2 | Issue 6 | e60 0613
Retroviral Integration-Target Selectionbecause they had been used in a previous study comparing
MLV and HIV integration targeting [14].
To clone integration sites, genomic DNA from infected
cells was extracted, digested with MseI and ligated to adapters.
The junctions between proviral DNA and genomic DNA were
ampliﬁed by nested PCR using primers complementary to
proviral and adaptor sequences, cloned, sequenced, and
mapped to the human genome as described [11,13,14,24].
Newly determined sets of integration sites (a total of 2,440
sites for the ﬁve viruses studied) were compared to each other
and to previously reported datasets (Table 1). The distribu-
tion of integration sites was also compared to random sites in
the human genome generated computationally. As is dis-
cussed in Protocol S1, a bioinformatic procedure was used to
control for potential biases in integration-site recovery due
to possible nonrandom distributions of restriction sites in the
human genome.
As a test for correct integration by the chimeric viruses, we
determined the target-site duplication lengths for a few
integration events of each chimeric virus (Figure 1C). Each
chimeric virus showed mostly the duplication length that is
characteristic of the virus donating the IN segment—4 bp for
MLV and 5 bp for HIV—which is as expected because IN is
known to dictate the length of the duplication [25,26]. For
unknown reasons, one out of ﬁve duplications for the
HIVmGagmIN chimera was 5 bp instead of the expected 4
bp; all the others were as expected. In addition, all integration
events showed evidence of correct cleavage at the viral DNA
39 end by integrase. These data support the idea that the IN–
DNA complexes of the chimeras generally assembled and
functioned normally.
The target DNA sequences at the point of integration were
then compared (Figure 1D). Previous studies showed that
retroviruses have weak preferences for speciﬁc primary DNA
sequences at integration sites and, when large numbers of
sites are analyzed, these biases become statistically very
signiﬁcant [4–7]. We found that two MLV datasets and the
HIVmGagmIN dataset showed the previously determined
MLV-favored site, and that the HIVPuro and HIVmGag
datasets matched the known HIV sequence. Unexpectedly,
the HIVmIN site showed lower information content than the
others and was somewhat intermediate in sequence. Pairwise
comparisons of selected positions in the consensus sequence
showed signiﬁcant differences (e.g., p , 0.0001 for compar-
ison of HIVmIN to HIVPuro at position  3; p , 0.0001 for
comparison of HIVmIN to MLVPuro at position 2, analyzed
by chi-square). This indicates that Gag determinants, as well
as IN determinants, can inﬂuence the favored primary
sequences at integration sites.
Integration Frequency near Transcription Start Sites and
CpG Islands
Integration sites for each of the ﬁve viruses were mapped to
the human genome, and nearby features were assessed (Figure
2). To begin to compare integration by the chimeras, we
evaluated the frequency of integration near transcription
start sites and CpG islands (Figure 3A and 3B; Table 2). The
MLVPuro control exhibited a strong preference for integra-
tion near transcription start sites—26.1% of MLVPuro sites
were within 6 5 kb of a RefSeq gene-transcription start site
compared to 5.0% of matched random control sites. For the
HIVPuro virus, only 6.9% were near transcription start sites.
Thus the preferential integration near transcription start
sites by MLV, but not HIV, reported previously [13,14] was
seen despite the puromycin selection of transduced cells (p ,
0.0001 for pairwise comparison of HIVPuro and MLVPuro;
chi-square test).
The HIVmIN and HIVmGagmIN target-site preferences
closely paralleled MLV, showing 20.7% and 22.4% of
integration events within 6 5 kb of transcription start sites,
respectively. These high frequencies were signiﬁcantly differ-
ent from HIVPuro (p , 0.0001 for both comparisons; chi-
square test), and the random control (Table 2), but not
signiﬁcantly different from MLVPuro (p . 0.05 for both
comparisons; chi-square test). HIVmGag differed, showing
only 3.9% of integration events near transcription start sites,
which was signiﬁcantly lower than HIVPuro (p ¼ 0.0342; chi-
square test). Thus MLV IN is a sufﬁcient determinant for
directing favored integration near transcription start sites,
and Gag-derived proteins also inﬂuence integration near
these features.
The integration frequency near CpG islands was then
compared. CpG islands are regions rich in the CpG
dinucleotide, which are undermethylated and frequently
associated with gene regulatory regions [27]. MLV strongly
favors integration near CpG islands while HIV does not
[11,14]. We quantiﬁed integration frequency near CpG
islands and found that the MLVPuro, HIVmIN, and HIVm-
GagmIN viruses all favored integration near these sites.
Speciﬁcally, 11.8%, 9.4%, and 9.9% of sites, respectively, were
within 1 kb of a CpG island midpoint, compared to 1.0% of
matched random sites. HIVPuro was not signiﬁcantly differ-
ent from random sites (0.2%), while the HIVmGag virus
signiﬁcantly disfavored regions within 1 kb of a CpG island
midpoint (0%, p ¼ 0.0224 for chi-square comparison to
random sites). The MLVPuro, HIVmIN, and HIVmGagmIN
datasets showed signiﬁcantly more frequent integration near
CpG islands than did the HIVPuro and HIVmGag datasets (p
, 0.0001 for any pairwise comparion between the two
groups; chi-square test).
In summary, the HIVmIN and HIVmGagmIN chimeras
Table 1. Integration-Site Datasets Used in This Study
Dataset Cell Type Number of
Integration Sites
Source
HIVPuro HeLa 525 This report
HIVmGag HeLa 493 This report
HIVmIN HeLa 352 This report
HIVmGagmIN HeLa 526 This report
MLVPuro HeLa 544 This report
MLV-Burgess HeLa 917 Wu et al. [14]
HIV-pooled Various
a 2,055 Carteau et al. [4]
Schroder et al. [13]
Wu et al. [14]
Mitchell et al. [11]
ASLV 293T-TVA, 834 Mitchell et al. [11]
HeLa Narezkina et al. [12]
L1 LINE HeLa 127 Gilbert et al. [30]
Symer et al. [31]
HIV-Burgess HeLa 290 Wu et al. [14]
aSupT1, HeLa, H9, IMR-90, and PBMC.
DOI: 10.1371/journal.ppat.0020060.t001
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near transcription start sites and CpG islands. Evidently, MLV
IN is sufﬁcient to direct favored integration near these
features. HIVPuro showed signiﬁcant differences from
HIVmGag, implicating Gag in integration targeting near
these features as well.
Another difference between HIV and MLV is the different
frequency of integration within transcription units (Table 2).
The HIVPuro virus favored integration in these sequences
(77.9% in RefSeq genes), while the MLVPuro virus showed a
much weaker trend (44.3% in RefSeq genes), which is only
slightly above the frequency for random sites (33.9%).
Comparing the frequency between HIVPuro and MLVPuro
achieved p , 0.0001 (chi-square test). The HIVmIN and
HIVmGagmIN viruses did not differ signiﬁcantly from the
MLVPuro virus (p-values are 0.1112 and 0.5713, respectively;
chi-square test). Both HIVmIN and HIVmGagmIN differed
signiﬁcantly from HIVPuro (p , 0.0001 for both comparisons;
chi-square test). HIVmGag showed an intermediate pheno-
type, being down signiﬁcantly in the frequency of targeting
transcription units compared to HIVPuro (reduced 11%; p ,
0.0001; chi-square test), but still signiﬁcantly greater than the
MLVPuro, HIVmIN, or HIVmGagmIN viruses (p , 0.0001 for
all comparisons; chi-square test). Thus, analysis of integration
frequency in transcription units also indicated that IN was
the key determinant, but gag also contributed.
We next assessed the effects of transcriptional activity on
integration frequency using transcriptional proﬁling data for
the HeLa target cells. All viruses tested favored active
transcription units for integration compared to randomly
selected genes (p , 0.0001, Mann-Whitney U-test on signal
values). The median expression level of genes targeted for
integration was highest for the HIVPuro and HIVmGag
viruses but lower for HIVmIN, HIVmGagmIN, and MLVPuro
viruses—in that order. The median signals were signiﬁcantly
different between the HIVPuro virus and the HIVmGagmIN
and MLVPuro viruses (p ¼ 0.0005 and p ¼ 0.0241; Mann-
Whitney U-test of signal values for genes targeted by HIVPuro
versus HIVmGagmIN and by HIVPuro versus MLVPuro,
respectively). Thus the chimeras containing MLV IN in the
HIV background paralleled MLV by this measure as well.
Integration Frequency near DNase I Cleavage Sites
Early studies of MLV integration targeting suggested that
MLV favors DNase I–hypersensitive sites for integration [8–
10]. DNase I–hypersensitive sites are believed to be nucleo-
some-depleted chromosomal regions associated with regu-
latory elements [28]. Genome-wide mapping of DNase I
cleavage sites in chromatin has revealed that they are
enriched near the 59 ends of transcription units, near CpG
islands, and near active genes, reinforcing the idea that they
are markers for regulatory regions [22,29].
To assess the correlation between retroviral integration
and DNase I cleavage frequency genome-wide, we quantiﬁed
integration sites within 1 kb of two positions of DNase I
cleavage mapped by Crawford et al. [22]. We chose to use two
cleavage sites in the analysis instead of a single site to better
match the experimental deﬁnition of DNase I–hypersensitive
sites, which relies on multiple cleavage events. The con-
clusions were similar whether one, two, or three DNase I
Figure 2. Positions of Retroviral Integration Sites on the Human Chromosomes
The human chromosomes are shown numbered. Centromeric regions (which are mostly unsequenced) are shown in gray. Relative gene density is
indicated in the top bar on each chromosome by the intensity of the cyan coloration. Integration-site datasets (lower bars) are color-coded as indicated.
Sites of integration near transcription start sites (within 6 5 kb), CpG islands (within 6 1 kb of a CpG midpoint), or 2 DNase I cleavage sites are shown as
red dashes; other sites are black.
DOI: 10.1371/journal.ppat.0020060.g002
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technical reasons, Crawford et al. analyzed cleavage sites in
resting T cells, but further analysis showed that 80% of sites
were shared between resting T cells and HeLa cells [22]; we
therefore extrapolated their data for comparison to integra-
tion sites in HeLa cells studied here.
Table 2 shows the percentage of integration sites that were
in intervals (plus or minus 1 kb of the integration sites)
Figure 3. Frequency of Integration near Transcription Start Sites, CpG Islands, and DNase I Cleavage Sites, Illustrating the Contribution of MLV IN to
Specificity
(A and B) The percentage of integration sites (per kb) within each interval is shown for (A) transcription start sites, and (B) CpG islands.
(C) DNase I cleavage sites, For each dataset, the proportion of integration sites found within 6 1 kb of two DNase I cleavage sites was divided by the
proportion in the matched random control set. The dotted line represents the expected bar height if the observed data did not differ from the random
control set. L1 is displayed as the ratio over an unmatched random set. Three asterisks denote p , 0.0001 by chi-square comparison to random sites.
Single asterisk denotes p ¼ 0.0396.
DOI: 10.1371/journal.ppat.0020060.g003
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ment relative to the matched random control is shown in
Figure 3C. We also analyzed previously published datasets
from MLV [14], HIV [4,11,13,14], ASLV [11,12], and the L1
retrotransposon [30,31] and plotted these in Figure 3C for
comparison.
Of these, MLV showed by far the strongest preference for
integration near DNase I cleavage sites. HIV and L1 retro-
transposons showed no preference for integration near DNase
I cleavage sites, while ASLV showed a weak preference that
barely achieved statistical signiﬁcance. Thus, contrary to the
expectation that open chromatin at DNase I cleavage sites is
globally favorable for integration, we ﬁnd that strong favoring
of integration near DNase I cleavage sites is speciﬁc to MLV.
DNase I cleavage sites are known to be enriched near
promoters, raising the question of whether the association of
DNase I cleavage sites and MLV integration sites is just a
reﬂection of favored integration near promoters. However, a
bioinformatic analysis of this issue (Protocol S2; unpublished
data) indicates that proximity to DNase I cleavage sites is
favorable for integration independently of proximity to
promoters. For example, when promoter locations are
approximated as the 1 kb of DNA just upstream from a
RefSeq transcription start site, analysis of integration sites
outside these regions still reveals increased frequency of MLV
integration plus or minus 500 bp from a DNase I cleavage site
(p , 0.00001).
HIVmIN and HIVmGagmIN were similar to the MLVPuro
virus in that they strongly favored DNase I–hypersensitive
sites for integration, and all three differed signiﬁcantly from
HIVPuro or HIVmGag (p , 0.0001 for any pairwise
comparison between the two groups; chi-square test). Like
the HIVPuro virus, the HIVmGag virus did not favor these
sites for integration above the expectation for random
placement (Table 2). Thus substituting MLV IN into HIV
was sufﬁcient to transfer the tendency to favor integration
near DNase I cleavage sites.
Transcription-Factor Binding Sites near Integration Sites
Given the favoring of integration by MLV, HIVmIN, and
HIVmGagmIN near promoters, we investigated whether
transcription-factor binding sites were enriched near inte-
gration sites of these viruses. We evaluated possible enrich-
ment of 546 transcription-factor binding-site motifs within
plus or minus 1 kb of integration sites compared to matched
random control sites. To assess the generality of any ﬁndings,
we also included in this study a previously published set of
MLV integration sites in HeLa cells (termed MLV-Burgess;
[14]). The MLVPuro, MLV-Burgess, HIVmIN, and HIVmGag-
mIN datasets showed by far the highest numbers of
signiﬁcantly (p , 0.001) enriched transcription-factor bind-
ing-site motifs (54, 33, 25, and 24, respectively). The HIVPuro
and HIVmGag returned far fewer (1 and 0). Strikingly, for the
MLV group of motifs, many were common to all four datasets,
or were shared between multiple group members (Figure 4).
Seventeen signiﬁcantly enriched factors were common to all
four, thus specifying a set of cellular factors correlated with
MLV (plus HIVmIN and HIVmGagmIN) integration (see
Table S1). No single motif was common between the HIVPuro
and HIVmGag datasets.
However, many of the sites in Figure 4 were not found to be
enriched when promoter sequences were used as controls
instead of randomly chosen genomic sites (see Table S1),
indicating the general features of promoters correlate most
strongly with MLV integration. Nevertheless, a few tran-
scription-factor binding sites were still signiﬁcantly enriched
when promoters were used as controls (requiring 1.5-fold
enrichment and p   0.001), suggesting potential speciﬁc
interactions. Among the datasets in Figure 4, binding sites for
the Ap-1 and Bach1 transcription factors were enriched
relative to promoter controls in three out of four datasets
(HIVmIN was the exceptional dataset). In addition, a
regression analysis indicated that the presence of a nearby
promoter could not fully account for the favorable effect of
transcription-factor binding sites on integration frequency,
again indicating a possible effect of the transcription-factor
binding sites beyond just marking promoters (Protocol S2).
Global Comparison of Trends in Integration Targeting
To assess the similarities among integration-site datasets, a
machine learning algorithm based on RandomForest was
developed to cluster the datasets, taking into account 109
different types of genomic features (Figure 5A; Protocol S3).
Examples of genomic features included: gene calls, CpG
islands, G/C content, DNase I cleavage sites, and gene
boundaries (a detailed list is included in Protocol S3). The
MLVPuro, HIVmIN, and HIVmGagmIN integration-site data-
sets were clustered together by this means. HIVmGagmIN
resembled MLV the most closely. HIVPuro and HIVmGag
clustered together, though the analysis also emphasized the
distinctions between the two datasets. The genomic features
most responsible for distinguishing among integration-site
datasets could be determined by further analysis of the
clustering results (summarized in Protocol S3). Measures of
Table 2. Integration near Genomic Features
Genomic Feature Percentage of Integration Sites (p-Values for Chi-Square Comparison to Random Sites)
Human Genome
(Matched Random
Sites)
HIVPuro HIVmGag HIVmIN HIVmGagmIN MLVPuro
Within 6 5 kb of a RefSeq transcription start site 5.0% 6.9% (0.0549) 3.9% (0.2452) 20.7% (,0.0001) 22.4% (,0.0001) 26.1% (,0.0001)
Within 6 1 kb of a CpG island midpoint 1.0% 0.2% (0.0544) 0.0% (0.0224) 9.4% (,0.0001) 9.9% (,0.0001) 11.8% (,0.0001)
Within RefSeq genes 33.9% 77.9% (,0.0001) 66.7% (,0.0001) 38.9% (0.0504) 42.6% (,0.0001) 44.3% (,0.0001)
With two DNase hypersensitive sites
in a window 6 1k b
1.0% 1.0% (0.8609) 1.6% (0.1998) 8.8% (,0.0001) 8.9% (,0.0001) 11.4% (,0.0001)
DOI: 10.1371/journal.ppat.0020060.t002
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were prominent, as were measures of integration in genes and
gene density, all as expected from the data in Table 2 and
Figure 3.
Another signiﬁcant featurew a st h eG / Cc o n t e n ta t
integration sites. The effects of G/C content in isolation are
presented in Figure 5B. For the highest G/C content category,
there are obvious, strong effects (p , 0.0005 for each
integration complex). In the human genome, regions of high
G/C content are also high in transcription units, SINE
elements, CpG islands, and a variety of other features.
Controlling for these features would be expected to reduce
the strength of the relationship shown in Figure 5B. However,
after controlling for the presence of a CpG island within
6 2.5 kb, the effects of being in the highest G/C content
category are still signiﬁcant (at p , 0.005 for each virus
studied). HIVPuro and HIVmGag differed by this measure
(particularly in the highest G/C content category where
p , 1e
 10), indicating that Gag proteins play a role in
integration targeting near these sequences.
Effects of Selection on Populations of Proviruses
In order to clone a large number of integration sites from
the poorly infectious chimeric viruses, it was necessary to
select infected cells with puromycin, raising the question of to
what extent the selection for proviral gene expression
affected the ultimate distribution of integration sites.
Previous work showed that selecting for proviral expression
can inﬂuence the population of integration sites recovered,
though the effect was modest [24]. To account for this,
puromycin-transducing HIV (HIVPuro) and MLV (MLVPuro)
control viruses were used in the present study for comparison
to the chimeras. Thus the data from this study, combined with
previous work, allows the effects of selection to be analyzed
by comparing the HIVPuro and MLVPuro datasets to
unselected HIV and MLV datasets (Wu et al. [14]; Table 1),
which were also generated by infection of HeLa cells. The
pairs of datasets were compared in a semiautomated fashion
with respect to many types of genomic annotation. The
results are presented in detail in Protocols S4 and S5, and
highlights are shown in Figure 6 and Table S2.
The unselected HIV-Burgess dataset did not differ signiﬁ-
cantly from the HIVPuro dataset over many forms of
annotation. For example, the two did not differ in the
frequency of integration in RefSeq genes (Figure 6A), the
proportion of sites within 1 kb of a CpG island, or the
proportion of sites within 1 kb of two DNase I cleavage sites
(Table S2). However, the two datasets did differ with respect
to the gene density of regions hosting integration sites
(p ¼ 0.0085 for gene density in a 4-Mb window surrounding
Figure 4. Diagram of the Relationship of Transcription-Factor Binding
Sites Enriched in the MLVPuro, MLV-Burgess, HIVmIN, and HIVmGagmIN
Integration-Site Datasets
The genomic sequences within 1 kb of each integration site were used
for analysis. Ten matched random-control integration sites were
compared to each experimental integration site. The cut-off value for
over-representation was 2.0-fold. All comparisons achieved p   0.001.
The number of enriched transcription-factor binding sites in each dataset
is shown with the number of factors unique to each in parentheses. The
edge labels show the number of commonly enriched sites between pairs
of datasets.
DOI: 10.1371/journal.ppat.0020060.g004
Figure 5. Effects of Gag Proteins on Integration Targeting
(A) Clustering by the machine learning algorithm RandomForest,
illustrating an influence of Gag determinants as well as IN. For a detailed
description of the method, see Protocol S3.
(B) An analysis of the G/C percentage at integration sites.
DOI: 10.1371/journal.ppat.0020060.g005
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Retroviral Integration-Target Selectioneach integration site; Protocol S4), as did the response to
transcriptional intensity in the surrounding region (Figure
6B). These data suggest that gene-dense regions are more
favorable for HIV provirus expression, reinforcing earlier
ﬁndings that integration within long intergenic regions
disfavored subsequent proviral gene expression [24].
The MLVPuro dataset did not differ from the unselected
MLV-Burgess dataset in the proportion of integration sites
within RefSeq genes (Figure 6C), within 5 kb of a RefSeq
gene-transcription start site, within 1 kb of a CpG midpoint,
or within 1 kb of two DNase I cleavage sites (Table S2).
However, like HIV, the selected and unselected MLV sites did
differ in their frequency in gene-dense regions (p , 2.22e
 16
for gene density in a 4-Mb window surrounding each
integration site; Protocol S5) and their response to local
transcriptional intensity (Figure 6D). Selected and unselected
MLV also differed in the G/C content at integration sites (p¼
4.52e
 11; see Protocol S5). Evidently, gene-dense regions and
correlated regions of high G/C content are favorable for MLV
gene expression after integration.
Discussion
Previous studies of target-site selection by mobile DNA
elements have revealed that the determinants of integration
targeting can be diverse. The prokaryotic transposons Tn7
and bacteriophage Mu each encode speciﬁc proteins, distinct
from the element-encoded transposase enzymes that bind to
integration-target DNA and direct site selection (reviewed in
[32]). For the Saccharomyces cerevisiae Ty retrotransposons, in
contrast, there is strong evidence for a tethering mechanism
involving direct binding of the Ty integrase enzyme to a
cellular protein bound near favored sites on target DNA [33–
37]. Here we report that two virus-encoded determinants are
Figure 6. Effects of Selection for Provirus Gene Expression on the Distribution of Integration Sites
(A) Frequencies of integration in RefSeq genes in the HIV-Burgess and HIVPuro datasets.
(B) Comparison of the relative frequency of integration in the HIV-Burgess and HIVPuro datasets as a function of transcriptional intensity. The
proportion of integration sites from each dataset in regions of varying transcriptional intensity was plotted increasing from left to right along the x-axis
(in groups divided according to deciles of density). For ‘‘expressed genes’’ in this plot, we counted the number of genes whose expression level in HeLa
cells was in the upper 1/8th of genes assayed on the HG-U133A microarray. The p-value given is the result of fitting a cubic polynomial to the expressed
gene-density values.
(C) Frequencies of integration in RefSeq genes in the MLV-Burgess and MLVPuro datasets.
(D) Comparison of the relative frequency of integration in the MLV-Burgess and MLVPuro datasets as a function of transcriptional intensity. See
Protocols S4 and S5 for details and additional plots.
DOI: 10.1371/journal.ppat.0020060.g006
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Retroviral Integration-Target Selectioninvolved for retroviruses: the IN protein and components of
the Gag polyprotein.
An alternative explanation for the data presented here
could have been that the viral nucleic acid sequence, and not
the encoded protein, was the determinant of target-site
speciﬁcity. As shown in Figure 1B, the viral DNAs that
become integrated retain the IN and gag coding regions. Thus
it appears possible that a binding site for a cellular protein
might exist in the DNA encoding IN or gag, and that binding
of a cellular factor to this DNA site could mediate
integration-site selection. However, this model can be ruled
out, because integration-site sequence data has been obtained
for both HIV and MLV using retroviral vectors that lack the
gag and IN coding regions, and these show the same target-
sequence preferences as the viruses that do contain the IN
and gag coding regions studied here (MLVPuro is such a
dataset for MLV, and [11,13] report examples for HIV). Thus
the IN and Gag-derived proteins are responsible for selecting
the integration target, and not a DNA site within the region
encoding gag or IN.
The earliest model for the mechanism of integration-site
selection by retroviruses proposed that open chromatin was
favored because MLV favored integration near DNase I–
hypersensitive sites [8–10]. However, our genome-wide data
indicate that DNase I–sensitive regions are not universally
favorable. Only MLV—and not HIV, ASLV, or L1—strongly
favored integration near to these sites. It is unclear whether
relatively greater exposure of DNA at DNase I–hypersensitive
sites is involved in integration targeting at all. Binding of
MLV integration complexes to speciﬁc cellular proteins
bound at or near DNase I–hypersensitive sites may fully
explain the observations. Contrary to the initial interpreta-
tion of the data on integration and DNase I–hypersensitive
sites, we conclude that none of the available data require
explanations based on DNA accessibility to explain integra-
tion targeting near these sites.
Another model for the mechanism of integration targeting
invokes effects of the cell cycle. HIV and MLV differ in the
cell-cycle dependence of infection. HIV can infect cells
regardless of cell-cycle phase [38,39], while MLV infection
requires host cells to pass through mitosis [40,41]. The
transcriptional state of a cell is known to vary with the cell
cycle, so the organization of chromosomal DNA encountered
by the MLV and HIV integration complexes should differ.
The HIVmGag chimera exhibited cell cycle–restricted in-
fectivity, like that of MLV [20]—thus HIVmGag would likely
encounter the chromosomal DNA in the same state as does
MLV. The targeting preferences of the HIVmGag chimera
did differ from those of HIVPuro, potentially supporting the
cell-cycle model, but the HIVmGag integration pattern was
very different from that of MLV. Thus cell-cycle effects may
have a modest inﬂuence on integration, but other factors
appear to dominate. Consistent with this, studies of HIV
integration targeting in non-dividing cells have not shown
large differences from studies of integration in dividing cells
[42–43].
The best-supported model at present invokes direct
tethering interactions between retroviral proteins and
cellular factors. Evidence suggests that HIV IN is one
determinant of integration targeting, since it binds LEDGF/
p75 protein [15–18], and cells lacking LEDGF/p75 show
reduced frequency of integration in transcription units [19].
However, the IN–LEDGF/p75 interaction is not a complete
explanation for the HIV integration-target preference,
because HIV integration in cells depleted for LEDGF/p75
shows only a modest reduction in integration in transcription
units, indicating that other factors may be involved [19].
Data reported here implicate IN as the primary determi-
nant of integration targeting, with Gag-derived proteins
playing an auxiliary role. For the MLV case, IN is clearly a
dominant determinant, because it reprograms HIV integra-
tion toward the MLV-like pattern. It is possible that
determinants for targeting HIV exist in other HIV genes,
but are recessive to MLV IN. However, the data with LEDGF
suggest that HIV IN is one determinant of HIV target-site
selection. The mechanism of MLV targeting is not fully
speciﬁed by our data, but a direct tethering interaction
between MLV IN and transcription factors (Figure 4; Table
S1) or other proteins bound at promoters is consistent with
our ﬁndings. The role of Gag is less clear. It could be that
MLV Gag–derived proteins are involved indirectly by acting
as cofactors for correct assembly of complexes containing
MLV IN. Consistent with this idea is the ﬁnding that the
target-sequence preference at the point of integration is
perturbed in the HIVmIN dataset, but fully matches MLV in
HIVmGagmIN (Figure 1D). That is, lack of the matched MLV
Gag may cause incorrect assembly of MLV IN, resulting in
incorrect recognition of the target DNA. MLV Gag could also
interact directly with cellular proteins. A third possibility is
that MLV Gag is acting through its ability to regulate the
relationship of integration to the cell cycle [20], as is discussed
above. Our results also suggest that HIV Gag–derived
proteins are involved in integration targeting, because the
HIVmGag chimera differed signiﬁcantly from HIVPuro in
target-sequence preferences (see, for example, Figure 5B).
In summary, we found that substitution of MLV IN for HIV
IN reprogrammed HIV integration-site selection towards that
of MLV. Furthermore, addition of MLV gag resulted in a
closer parallel with MLV integration targeting. In addition,
we found that favored integration near DNase I–hyper-
sensitive sites was an MLV-speciﬁc trend, and this tendency
also could be transferred to HIV by substituting MLV IN into
HIV. These data clarify the viral determinants of integration-
site selection, reveal a new role for Gag proteins, and
constrain models for the mechanisms directing integration
targeting by retroviruses.
Materials and Methods
DNA constructions. To generate the MLVPuro dataset, we used
LPCX (Clontech, Palo Alto, California, United States), which is an
MLV-based vector that expresses the puromycin resistance gene from
the MLV LTR. All other vectors used were based on the full-length
HIV clone pLAI [44]. Vpr was mutated by the insertion of four bases
at the NcoI site at 5,207 bp, and env has a deletion between the BglII
sites at 6,634 and 7,214 bp [23]. The puromycin resistance gene was
cloned in place of nef. The MLV gag gene segment encoding MA, p12,
and CA from pAMS [45] was cloned in place of HIV MA and CA for
MHIV-mMA12CA-DenvDvprDnef-puromycin (for the HIVmGag da-
taset) and MHIV-mMA12CA-mIN-DenvDvprDnef-puromycin (for
HIVmGagmIN) as described previously [20]. For MHIV-mIN-
DenvDvprDnef-puromycin (HIVmIN) and MHIV-mMA12CA-mIN-
DenvDvprDnef-puromycin (HIVmGagmIN), the MLV IN–encoding
portion of the pAMS pol gene was cloned in place of HIV IN, starting
at the same position of the 59 end of the HIV IN gene segment. The 39
end of the HIV IN–encoding region with the cPPT remains and is
separated from the end of MLV IN by two stop codons [21]. (The
junction sequence is CGTGGAAGCCCTTAATAGTCTgaattc.)
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previously [20]. HeLa cells were infected by spinoculation [46] with
concentrated viral supernatant and 20 lg/ml DEAE-dextran. Infected
cells were selected with 0.7 lg/ml puromycin for 2 wk. Genomic DNA
was extracted from pooled colonies.
Cloning integration sites. Genomic DNA was digested with MseI
and ligated to a linker as described previously [14]. The ligase was
heat-inactivated at 65 8C for 15 min, and the genomic DNA was
digested with a second restriction enzyme to limit the ampliﬁcation
of an internal viral fragment. SpeI was used for the MLVPuro virus,
and SacI was used for the HIV-based viruses. Viral-host DNA
junctions were ampliﬁed by nested PCR using primers speciﬁc for
the proviral LTR (reading out from the 39 end) and the linker
essentially as described in the GeneWalker Kit manual (Clontech).
Nested-PCR products were cloned using the TOPO TA cloning
system (Invitrogen, Carlsbad, California, United States). Clones were
sequenced and mapped to the human genome with BLAT (University
of California, Santa Cruz, California, United States). The viral
genotypes in each genomic DNA sample were conﬁrmed by PCR
using primers that detected sequences from HIV gag, HIV IN, MLV
gag, and MLV IN.
For analysis of the length of target-site duplications, integration-
site clones were randomly chosen and genomic sequence-speciﬁc
primers were designed. The viral-host DNA junction from the 59 LTR
of the provirus was ampliﬁed from undigested genomic DNA and
cloned using the TOPO TA cloning system (Invitrogen). Oligonucleo-
tides used in this study are listed in Table S3.
A question arises regarding the use of the VSV-G envelope for
infection instead of the authentic HIV or MLV envelopes, but a direct
study of this issue has failed to reveal any differences [43].
Bioinformatic analysis. A detailed statistical analysis is presented
in Protocols S1–S5. In order to control for possible biases in the
datasets due to the choice of restriction endonuclease used in cloning
integration sites, each experimental integration site was paired with
ten randomly selected sites in the genome that were exactly the same
distance from an MseI site. These matched random control sites were
generated in silico and were used for comparison to the integration-
site datasets as previously described [11].
The statistical analysis of favored binding-site motifs (Figure 4 and
Table S1) was carried out as follows. Transcription-factor binding-site
motifs, described as positional-weight matrices, were obtained from
the TRANSFAC database. Let X and Y denote sets of signiﬁcant
motifs around the integration sites in two independent experiments,
with c motifs in common. Assuming a random sampling of jXj and jYj
distinct factors from a pool of 546 transcription-factor motifs, the
hypergeometric p-value estimates the probability of sampling c or
more common motifs.
For the analysis of the effects of host-cell transcription on
integration, we acquired a set of HeLa transcriptional proﬁling data
(assayed with Affymetrix HG-U133A microarrays [Santa Clara,
California, United States]) from NCBI Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/projects/geo/index.cgi).
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